14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
VOR vs MRNA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
VOR Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 5–5 Matrix Metrics)
VOR Overall Winner
6-Pillar Tally: VOR 3 – 3 MRNA
Matrix Metrics: VOR 5 – 5 MRNA
As of Nov 20, 2026, Vor Biopharma Inc. (VOR) is the stronger overall head-to-head candidate over Moderna, Inc. (MRNA) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). VOR carries a Unified Composite Score of 62.7/100 (BUY) at $19.19 (N/M Forward P/E, 0.0% operating margin), whereas MRNA carries 40.3/100 (SELL) at $195.00 (23.0x Forward P/E, -80.8% operating margin).
Growth vs. Quality Trade-Off: VOR earns the overall head-to-head edge with a stronger Unified Composite Score (62.7/100 BUY vs. MRNA 40.3/100 SELL) and 1.61β · 62% Vol risk profile, whereas MRNA leads top-line expansion (+29.2% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: VOR is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.3); meanwhile MRNA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 41.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VOR vs MRNA. Trailing 12-month operating profitability (VOR 0.0% vs MRNA -80.8%) and valuation multiples (VOR N/M vs MRNA 23.0x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $80.7B market capitalization and -80.8% operating margin.
OpEx & R&D Reinvestment38.8% of Rev ($980M)
90D Engineering Disclosures0 Published · mRNA Therapeutics
Investor FAQ VOR vs MRNA Key Questions & Quantitative Answers
As of Nov 20, 2026, Vor Biopharma Inc. (VOR) is the stronger overall head-to-head candidate over Moderna, Inc. (MRNA) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). VOR carries a Unified Composite Score of 62.7/100 (BUY) at $19.19 (N/M Forward P/E, 0.0% operating margin), whereas MRNA carries 40.3/100 (SELL) at $195.00 (23.0x Forward P/E, -80.8% operating margin). Growth vs. Quality Trade-Off: VOR earns the overall head-to-head edge with a stronger Unified Composite Score (62.7/100 BUY vs. MRNA 40.3/100 SELL) and 1.61β · 62% Vol risk profile, whereas MRNA leads top-line expansion (+29.2% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: VOR is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.3); meanwhile MRNA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 41.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
MRNA leads the Growth & Scale pillar: VOR posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with MRNA at +29.2% YoY revenue growth and -85.1% YoY earnings growth on $2.52B TTM revenue (-42.0% gross margin, -80.8% operating margin). On trailing 12-month operating scale, VOR generates N/A in USD-normalized revenue versus $2.52B for MRNA. In operating R&D and SG&A reinvestment, VOR deploys N/A (0 90-day corporate R&D disclosures) versus 38.8% of Rev ($980M) (0 disclosures) for MRNA.
MRNA screens cheaper on headline valuation multiples. VOR trades at N/M Forward P/E, 0.1x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas MRNA trades at 23.0x Forward P/E, 23.0x Trailing P/E, N/M PEG, and 33.1x EV/Revenue (-81.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VOR (-125.4% ROE) versus MRNA (-34.5% ROE) capital efficiency.
In options market volatility and institutional positioning, VOR carries 120.9% implied volatility (6th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.61β · 62% Vol realized risk). By comparison, MRNA carries 89.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 1.05x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (2.23β · 78% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.